Crucially, this splicing switch converged on activation of AKT signaling characterized by elevated p-AKT and p-S6 in resistant tumors (Fig. 6F,G), mirroring what was observed in MAPKi-resistant melanoma cell lines. The gene discussed is AKT1; the disease is melanoma.